Zhuhai Trinomab Pharmaceutical Co., Ltd
A New Paradigm in Tetanus Prevention

Tetanus, a potentially fatal disease caused by the bacterium clostridium tetani, has long been a global health concern. Even with treatment, the mortality rate for tetanus can range from 30 to 50 percent, and if left untreated, it can escalate to 100 percent.

Traditional methods for preventing tetanus rely on the vaccination shots given in childhood and adolescence. However, plasma-derived products obtained from human blood donations, containing hightiter anti-tetanus antibodies, must be administered to individuals who have not been vaccinated, have uncertain vaccination status, or have declined immunity. This is especially crucial when they sustain injuries, and the wounds are contaminated.

Plasma-derived products pose significant concerns, which include the risk of transmitting unknown diseases despite rigorous testing and the inconsistency in supply of plasma-derived products, leading to worldwide shortages.

In response to these challenges, Zhuhai Trinomab Pharmaceutical, a forward-thinking clinical-stage biopharmaceutical company, has introduced a first-in-class solution – TNM002 injection. It is a monoclonal antibody developed through the company’s proprietary HitmAb^® technology platform, which has emerged as a pioneer in discovering fully native human monoclonal antibodies (mAbs) to combat infectious diseases and other health conditions.

The HitmAb^® platform boasts differentiated advantages, particularly exceptional efficiency in discovering fully native human mAbs. These mAbs closely resemble those naturally produced by the human body, making them highly effective and safe.

The core functionality of this innovative platform involves leveraging its comprehensive capabilities to isolate antibody genes from the identified human single B cells with specificity or specific ability targeting particular pathogens or antigens. The result is the acquisition of natural, human monoclonal antibodies that faithfully mirror human antibody immunity.

Some countries, including China, use animalderived anti-sera from horses. In the case of China, they utilize a product known as equine Anti-Tetanus-Toxin, considered potentially hazardous. Developed countries ceased using them in the 1960s, and the World Health Organization (WHO) removed them from the essential drug list decades ago.

Zhuhai Trinomab Pharmaceutical is doing just that; it completed the entire clinical development program within an astonishing three-year timeframe. Its journey has been nothing short of remarkable. The development of this monoclonal antibody commenced in late 2020 with a phase one trial in Australia, a testament to the efficiency and agility of the Zhuhai Trinomab Pharmaceuticals team.

“This accomplishment shines as an example of the successful synergy between strategic planning, innovative clinical trial design, and effective execution,” says Wanmei Wang, MD, PhD, chief medical officer and senior vice president of Zhuhai Trinomab Pharmaceutical.

The accelerated progress of TNM002 has led to the “Breakthrough” designation from the China NMPA and the US FDA “Fast-track” designation, respectively, which underscores the impressive pace of innovation within the biopharmaceutical industry, with TNM002 set to revolutionize tetanus treatment.

Establishing a highly skilled clinical development team was vital to TNM002’s success. It came into existence within two years, comprising experienced and motivated individuals who drive the program’s success.

Zhuhai Trinomab Pharmaceutical is headquartered in Zhuhai, a city known for its scenic coastal beauty near Macau and Hong Kong. Rooted in this locale, Zhuhai Trinomab embodies a robust global vision, propelling its innovative solutions worldwide and catalyzing transformative changes in healthcare.

Zhuhai Trinomab Pharmaceutical’s exceptional journey is shaped by its visionary founders, Dr. Huaxin Liao and Weihong Zheng. Dr. Liao, the Chairman and CTO, is a global pioneer in virology research with over 40 years of scientific expertise. Weihong Zheng, the president and CEO, brings over 20 years of leadership in healthcare, having founded and led innovative biotech companies. Together, they drive Zhuhai Trinomab’s success with a blend of scientific excellence and strategic acumen in healthcare management.

It provides a compelling example of how cutting-edge technology and dedicated teamwork can bring about transformative change in healthcare. As TNM002 progresses, it has the potential to provide safer and more effective treatment options for those at risk of tetanus, saving lives and improving the quality of healthcare globally.